SCYNEXIS (SCYX) AI Stock Analysis

• Market Cap: $33.57M
• Dividend Yield: N/A
• Average Volume (3M): 131.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: -97.33%
• EPS Growth: -136.16%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 70
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.46
• Shares Outstanding: 38,981,064
• 10 Day Avg. Volume: 115,008
• 30 Day Avg. Volume: 131,532
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 10.82
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.50
• Price Target Upside: 417.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

SCYNEXIS struggles with significant financial challenges, including declining revenue, negative profitability, and cash flow issues, significantly impacting its stock performance. Technical indicators reinforce a bearish outlook, while valuation metrics reflect high risk and unattractiveness. The absence of positive triggers from earnings calls or corporate events further weighs on the stock's prospects.

Positive Factors

Drug Development

Scynexis has full rights to the next-generation antifungal SCY-247, which is in Phase 1 development.

Financial Stability

Scynexis has sufficient capital to reach milestones with $75M in cash, providing a financial runway into mid-2026.

Partnerships and Collaborations

The company received a $10M milestone payment from GSK following the submission of clinical study reports for the FURI, CARES, and NATURE studies.

Negative Factors

Manufacturing Issues

Lowering the 12-month price target to $4.00, from $8.00, due to ongoing uncertainty with GSK on manufacturing issues related to Brexafemme commercialization.

Revenue Risk

Uncertainty around the timelines for Brexafemme commercial royalties and GSK's potential filing for approval in invasive fungal infections increases the revenue risk adjustment to 50%.

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc. (SCYX) is a biotechnology company focused on the research, development, and commercialization of novel antifungal treatments. The company's core product is ibrexafungerp, an antifungal agent used to treat a variety of serious fungal infections. SCYNEXIS operates primarily within the pharmaceutical and biotechnology sectors, and its mission is to address unmet medical needs in fungal infection management through innovative therapies.

How the Company Makes Money

SCYNEXIS generates revenue primarily through the sale and licensing of its proprietary antifungal medications, particularly ibrexafungerp. The company earns money by commercializing its products in partnership with other pharmaceutical companies and through direct sales in markets where it holds regulatory approval. SCYNEXIS may also receive milestone payments, royalties, and upfront fees from strategic collaborations and licensing agreements with other firms seeking to develop and distribute its antifungal therapies in various regions. Additionally, the company might engage in research and development collaborations that could provide financial support through grants or co-development agreements.

SCYNEXIS Financial Statement Overview

Summary

SCYNEXIS faces multiple financial challenges with declining revenue and profitability, a moderately leveraged balance sheet, and negative cash flow trends. The company needs to address its operational inefficiencies and improve its cash flow to enhance financial stability.

Income Statement

SCYNEXIS shows significant volatility in its revenue and profitability. The revenue decreased sharply in 2024 from the previous year, and the company experienced a substantial net loss. The EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio and relatively stable stockholders' equity. However, the equity ratio is low, suggesting a higher reliance on liabilities, which could be risky.

Cash Flow

The cash flow situation is concerning, with negative free cash flow and operating cash flow. The company has not been able to generate positive cash flow from its operations, indicating a potential liquidity issue.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.75M	140.14M	5.09M	13.16M	0.00
	Gross Profit
3.75M	124.52M	4.46M	12.85M	-303.00K
	EBIT
-37.12M	72.67M	-85.76M	-60.83M	-51.15M
	EBITDA
-20.31M	73.48M	-59.91M	-31.41M	-51.15M
	Net Income Common Stockholders
-21.29M	67.04M	-62.81M	-32.87M	-55.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
16.05M	74.36M	73.50M	104.48M	93.04M
	Total Assets
90.64M	128.41M	87.81M	119.84M	102.54M
	Total Debt
16.27M	15.08M	48.60M	43.63M	19.84M
	Net Debt
219.00K	-18.97M	2.78M	-60.86M	-73.20M
	Total Liabilities
35.57M	55.45M	84.58M	78.58M	79.78M
	Stockholders Equity
55.08M	72.96M	3.23M	41.26M	22.76M
Cash Flow		Free Cash Flow
-24.01M	60.16M	-79.89M	-55.73M	-49.36M
	Operating Cash Flow
-24.01M	60.16M	-79.88M	-54.56M	-49.35M
	Investing Cash Flow
6.15M	-34.88M	-27.39M	-1.17M	6.47M
	Financing Cash Flow
-139.00K	-36.72M	48.60M	67.12M	94.00M

SCYNEXIS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.87 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.01, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.56 is Neutral, neither overbought nor oversold. The STOCH value of 4.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.

SCYNEXIS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
SCYX	42 Neutral	$33.57M	―	-33.25%	―	-97.33%	-136.16%
VTGN	42 Neutral	$59.17M	―	-46.28%	―	-33.00%	54.91%
MIST	41 Neutral	$40.02M	―	-277.55%	―	-100.00%	51.19%
XTLB	39 Underperform	$14.92M	―	-25.70%	―	―	86.44%
FBRX	38 Underperform	$38.77M	―	-80.82%	―	―	43.64%
CARA	29 Underperform	$22.25M	―	-270.01%	―	-65.96%	40.80%